Alzheimer s Research & Therapy 2020Brain imaging & connectomics Centre National de la Recherche Institut national de recherche e Inserm Sorbonne Université Institut du Cerveau Istituto delle Scienze Neurologi

Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD

Federica Cacciamani, Luisa Sambati, Marion Houot, Marie‐Odile Habert, Bruno Dubois, Stéphane Epelbaum, on behalf of the INSIGHT-PreAD study group, Christelle Audrain, Alexandra Auffret, Hovagim Bakardjian, Filippo Baldacci, Bénédicte M Batrancourt, Ismahane Benakki, Habib Benali, Hugo Bertin, Anne Bertrand, Laurie Boukadida, Federica Cacciamani, Valérie Causse-Lemercier, Enrica Cavedo, S. Cherif Touil, Patrizia Andrea Chiesa, Olivier Colliot, Gianfranco Dalla Barba, M. Depaulis, Angela Dos Santos, Bruno Dubois, M. Dubois, Stéphane Epelbaum, Bertrand Fontaine, Hélène Francisque, Geoffroy Pierre Gagliardi, Alexis Génin, Rémy Genthon, Pauline Glasman, F. Gombert, Marie‐Odile Habert, Harald Juergen Hampel, H. Hewa, Marion Houot

Published Oct 14, 202025 citationsPaper ↗

67%

OverallHighly rated

OverallHighly ratedVote to see the score

Readers

–

Only vote on papers you've read. Sign in to vote.

AI panel5/20reviewers recommend it

lenient 1/5

medium 2/10

strict 2/5

AI panel?Vote to see what the 20 AI reviewers said

Abstract

BACKGROUND: Lack of awareness of cognitive decline (ACD) is common in late-stage Alzheimer's disease (AD). Recent studies showed that ACD can also be reduced in the early stages. METHODS: We described different trends of evolution of ACD over 3 years in a cohort of memory-complainers and their association to amyloid burden and brain metabolism. We studied the impact of ACD at baseline on cognitive scores' evolution and the association between longitudinal changes in ACD and in cognitive score. RESULTS: 76.8% of subjects constantly had an accurate ACD (reference class). 18.95% showed a steadily heightened ACD and were comparable to those with accurate ACD in terms of demographic characteristics and AD biomarkers. 4.25% constantly showed low ACD, had significantly higher amyloid burden than the reference class, and were mostly men. We found no overall effect of baseline ACD on cognitive scores' evolution and no association between longitudinal changes in ACD and in cognitive scores. CONCLUSIONS: ACD begins to decrease during the preclinical phase in a group of individuals, who are of great interest and need to be further characterized. TRIAL REGISTRATION: The present study was conducted as part of the INSIGHT-PreAD study. The identification number of INSIGHT-PreAD study (ID-RCB) is 2012-A01731-42.